Vor Biopharma Inc.VOR
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · vorbio.com
Vor Biopharma is a clinical-stage biotechnology company. Following a strategic shift it is developing telitacicept, an anti-BLyS/APRIL fusion protein licensed from RemeGen, for autoimmune indications including generalized myasthenia gravis.
Key ratios
ROA
-21.4%TTM
2025
-70.4%2024
-44.4%2023
-31.7%
ROE
-125.4%TTM
2024
-94.5%2023
-58.7%
Recent news
Vor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
Track VOR in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer